Guadecitabine vs treatment choice in newly diagnosed acute myeloid leukemia: a global phase 3 randomized study.

However, these analyses had an inherent bias in that they excluded patients who died early, and there was a nonsignificant trend of early mortality with guadecitabine from the 60-day mortality data.

also in 5,406 other papers